# Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease

> **NCT02177344** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 646 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Low dose of Ipratropium bromide
- **DRUG:** High dose of Ipratropium bromide
- **DRUG:** Atrovent
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02177344
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-08
- **Primary completion:** 1999-10
- **Final completion:** —
- **Target enrollment:** 646 (ACTUAL)
- **Last updated:** 2014-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02177344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02177344, "Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02177344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*